Spectrum reports Phase II data for poziotinib in NSCLC
Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) reported interim data from 11 evaluable patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations who received ≥1 prior systemic treatment showing that poziotinib (HM781-36B, NOV12010) led to an objective response rate (ORR) of 73%, including 8 partial responses. Data were presented at the World Conference on Lung Cancer in Yokohama.
On a conference call to discuss the data, John Heymach said that in retrospective studies, median response rates to other therapies have been 4-8% among exon 20-mutant patients, and progression-free survival (PFS) averages less than 2 months. Heymach is a professor at the University of Texas MD Anderson Cancer Center, where the single-center trial was conducted. According to MD Anderson, the EGFR exon 20 mutation is present in about 2% of NSCLC patients...